GlassScriptPhysician profile
Karl E Hofammann
NPI 1740258698
$289.54
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $88.65 · 2021: $29.07 · 2022: $26.06.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $103.10 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.27 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $26.06 | 2022 | |
| Ferring Pharmaceuticals INC. | $18.47 | 2020 | |
| Amgen INC. | $16.77 | 2019 | |
| Vericel Corporation | $16.08 | 2019 | |
| Amarin Pharma, INC. | $15.49 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.89 | 2019 | |
| Eisai INC. | $13.73 | 2020 | |
| Merck Sharp & Dohme LLC | $13.58 | 2021 | |
| Adlon Therapeutics L.P. | $12.10 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karl Hofammann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.